Loading…
Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.
Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.
Nearly all revenue is Briumvi sold in the US to infusion centres, clinics and hospitals through specialty distributors and reimbursed by insurers. After withdrawing its earlier lymphoma drug Ukoniq in 2022, it is a one-product company.
Moat: narrow (IP / patents, installed base). Differentiated shorter-infusion anti-CD20 antibody competing for share in a crowded MS market.
Headquarters: New York, New York, United States · Founded: 1993 · Employees: 399
Size TG Therapeutics (TGTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.16B, the 817th largest of 3,117 United States companies the cockpit tracks. Shares closed at $59.83 on 6 Nov 2026.
Performance Over six months the shares gained 39.6%, against +8.1% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 76.1% over the last twelve months (peer median +15.3%); the operating margin is 17.1% (peer median 10.1%).
Valuation It trades at 30.9× forward earnings against a peer median of 30.6× (7th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is +427%, so the hurdle is -376 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points below its cost of capital (13.6% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $800M | $616M | $329M | $234M | $2.79M |
| Revenue growth | — | +87% | +41% | +8,290% | — |
| Gross profit | $659M | $516M | $290M | $219M | $2.00M |
| EBITDA | $137M | $125M | $42.2M | $21.1M | -$192M |
| Net income | $441M | $447M | $23.4M | $12.7M | -$198M |
| Free cash flow | $17.4M | -$25.0M | -$40.6M | -$31.4M | -$176M |
| Capital expenditure | $491,000 | $214,000 | $45,000 | $0 | $14,000 |
| Total debt | $754M | $254M | $254M | $111M | $83.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| TG Therapeutics TGTX | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 19.6× | 0.9% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 18.4× | 1.7% |
| Biogen BIIB | $36.7B | +28% | +2% | 17% | 16.8× | 9.4% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 9.6× | -5.4% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 9.7× | -12.9% |
| Merck KGaA MRK.DE | $72.5B | +23% | 0% | 20% | 17.5× | 7.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TGTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.2% | +5.0% | 7th highest of 21 |
| 6-month return | +39.6% | +8.1% | 3rd highest of 21 |
| Distance from 52-week high | -5.9% | -16.5% | 6th highest of 21 |
| Revenue growth (TTM) | +76.1% | +15.3% | 3rd highest of 20 |
| Operating margin | 17.1% | 10.1% | 8th highest of 19 |
| Forward P/E | 30.9× | 30.6× | 7th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 50.3% | 13.8% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +426.7% | +9.3% | highest of 13 |
| Hurdle (Req g minus delivered) | -376.4 pp | +4.0 pp | least demanding of 13 |
| ROIC minus cost of capital | -0.3 pp | +1.1 pp | 8th lowest of 17 |
| EV / EBITDA | 68.1× | 24.3× | most expensive of 10 |
| Net debt / EBITDA | 1.5× | -0.1× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% | +6.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 6.6× | -10.3% | +7.4% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 29.2× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |